Dr SCHOTT Roland

Innovative Dose-Response Assessment of the Metaboreflex With Indirect Control of Intramuscular Metabolic Perturbation in Humans.

Kouzkouz N, Mallard J, Hucteau E, Schott R, Pivot X, Ducrocq GP, Hureau TJ

Acta Physiol (Oxf). 2026 10;242(10):e70303

CDKN2A alterations in solid tumors: From biological mechanisms to clinical applications, with special emphasis on central nervous system tumors.

Wolf T, Berry N, Geyer L, Weingertner N, Pencreach E, Noel G, Schott R, Todeschi J, Entz-Werlé N, Chenard MP, Martin S, Reita D, Lhermitte B

Histol Histopathol. 2026 09 22;:25139

Treatment patterns and outcomes in advanced and metastatic lung cancer in France: Results from the Epidemiological Strategy and medical Economics (ESME) database lung cancer in France.

Girard N, Carton M, Macouillard P, Debieuvre D, Quantin X, Audigier-Valette C, Léna H, Filleron T, Gervais R, Schott R, Remon J, Justeau G, Bosquet L, Martin AL, Chouaid C, Pérol M

Lung Cancer. 2026 08 19;220:109585

Impairments in mitochondrial dynamics and morphology in skeletal muscle of breast cancer patients after a single paclitaxel administration.

Mallard J, Hucteau E, Somme L, Bischoff H, Demais V, Silvestrin P, Charles AL, Schott R, Pivot X, Hureau TJ, Pagano AF

Exp Physiol. 2026 07 1;:

From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma : FROST: multimodal treatment for GBM recurrence.

Barbe-Richaud JB, Cebula H, Todeschi J, Santin MDN, Baloglu S, Schott R, Cotton M, Blouet A, Bobin M, Noël G, Somme L

J Neurooncol. 2026 06 23;178(3):

Prolonged complete metabolic response to chemotherapy combined with amivantamab with high grade cutaneous toxicity after osimertinib resistance in an uncommon -mutant lung adenocarcinoma: a case report.

Barbe-Richaud JB, Pencreach E, Schott R, Holder E, Somme L

Transl Lung Cancer Res. 2026 04 30;15(4):110

NF-κB signaling drives rapid skeletal muscle atrophy in patients with breast cancer: The cost of fighting cancer with chemotherapy.

Mallard J, Debrut L, Hucteau E, Somme L, Bischoff H, Moinard-Butot F, Coliat P, Bendjama A, Weltzer L, Sharifi Tafreshi A, Billand C, Charlot A, Boutonnet L, Laverny G, Keime C, Favret F, Schott R, Pivot X, Hureau TJ, Pagano AF

Am J Physiol Cell Physiol. 2026 04 16;:

Feasibility and Potential Effects of Exercise Training Combining Eccentric and Concentric Cycling in Patients With Breast Cancer.

Hucteau E, Hureau TJ, Decor A, Weltzer L, Kouzkouz N, Bischoff H, Somme L, Schott R, Pivot X, Pagano AF, Mallard J

Eur J Sport Sci. 2026 04;26(4):e70153

Prediction of survival and outcomes with depth of response at 6 months in metastatic non-small-cell lung cancer patients treated with chemotherapy and immunotherapy combination: SPORE trial.

Moinard-Butot F, Barbe-Richaud JB, Lasvergnas J, Ancel J, Justeau G, Le Floch H, Somme L, Chouaid C, Bylicki O, Schott R

ESMO Open. 2026 01 29;11(2):106042

Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review.

Bischoff H, Gendarme S, Somme L, Chouaid C, Schott R

Curr Oncol. 2025 11 6;32(11):

EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.

Menis J, Greiller L, Demontrond P, Monnet I, Novello S, Livi L, Young R, Decroisette C, Cloarec N, Robinet G, Schott R, Fayette J, Banna GL, De Marinis F, Califano R, Duchemann B, Luciani A, Colantonio I, Fournier B, Pretzenbacher Y, Caramella C, Silva M, Berghmans T, Dingemans AM, Bironzo P, Tugwood J, Zhou C, Hill S, Bradbury K, Morris K, Kilgour E, Dive C, Blackhall F, Besse B

Eur J Cancer. 2025 10 30;231:116059

Real-world survival and prognostic factors in WHO 2021 classified gliomas treated with chemo-radiotherapy.

Bilski M, Noël G, Smółka K, Kuncewicz K, Kuźnicki W, Feuvret L, Korab K, Peszyńska-Piorun M, Korona P, Baranowska I, Suleja A, Le Fevre C, Schott R, Somme L, Chabli S, Mesny E, Mastroleo F, Kotecha R, Jurkiewicz J, Fijuth J, Jereczek-Fossa BA, Krystkiewicz K, Harat M, Kuncman Ł

Sci Rep. 2025 10 30;15(1):38011

Tracking cancer-related fatigue during chemotherapy: Insights from a comparative cohort study of early breast cancer patients.

Mallard J, Hucteau E, Schott R, Pivot X, Pagano AF, Hureau TJ

Int J Cancer. 2025 06 10;:

Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study.

Mourlanette J, Rousseau-Bussac G, Mallah S, Guisier F, Zalcman G, Veillon R, Audigier-Valette C, Roa M, Nicolle I, Doubre H, Cloarec N, Lamy R, Morel H, Curcio H, Lagrange A, Schott R, Sabatini M, Toffart AC, Pinsolle J, Bennouna J, Chouaid C, Mazieres J

Target Oncol. 2025 03 13;:

LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer.

Swalduz A, Schiffler C, Curcio H, Ambasager B, Le Moel G, Debieuvre D, Dot JM, Duruisseaux M, Fournel P, Odier L, Demolombe S, Bizieux-Thaminy A, Peytier A, Schott R, Hominal S, Tissot C, Bombaron P, Metzger S, Donnat M, Ortiz-Cuaran S, Rosenfeld N, Pipinikas C, Saintigny P, Pérol M

J Thorac Oncol. 2024 12 16;:

Brain Metastases as Inaugural Sign of Non-Small Cell Lung Carcinoma: Case Series and Review of Literature.

Pușcașu A, Moinard-Butot F, Nannini S, Fischbach C, Schott R, Bender L

Cancers (Basel). 2024 09 8;16(17):

Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database.

Cabart M, Mourey L, Pasquier D, Schneider S, Léna H, Girard N, Chouaid C, Schott R, Hiret S, Debieuvre D, Quantin X, Madroszyk A, Dubray-Longeras P, Pichon E, Baranzelli A, Justeau G, Pérol M, Bosquet L, Cabarrou B

J Geriatr Oncol. 2024 07 26;:101819

Impact of Eccentric versus Concentric Cycling Exercise on Neuromuscular Fatigue and Muscle Damage in Breast Cancer Patients.

Hucteau E, Mallard J, Barbi C, Venturelli M, Schott R, Trensz P, Pflumio C, Kalish-Weindling M, Pivot X, Favret F, Ducrocq GP, Dufour SP, Pagano AF, Hureau TJ

Med Sci Sports Exerc. 2024 06 27;:

Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers.

Somme LB, Chouaid C, Moinard-Butot F, Barbe-Richaud JB, Greillier L, Schott R

BioDrugs. 2024 05 20;:

Outcomes of non-small cell lung cancer patients with non-V600E mutations: a series of case reports and literature review.

Lazar R, Fischbach C, Schott R, Somme L

Front Oncol. 2024 03 27;14:1307882

Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort.

Nannini S, Guisier F, Curcio H, Ricordel C, Demontrond P, Abdallahoui S, Baloglu S, Greillier L, Chouaid C, Schott R

Curr Oncol. 2024 03 21;31(3):1656-1666

A single chemotherapy administration induces muscle atrophy, mitochondrial alterations and apoptosis in breast cancer patients.

Mallard J, Hucteau E, Bender L, Moinard-Butot F, Rochelle E, Boutonnet L, Grandperrin A, Schott R, Pflumio C, Trensz P, Kalish-Weindling M, Charles AL, Gény B, Favret F, Pivot X, Hureau TJ, Pagano AF

J Cachexia Sarcopenia Muscle. 2024 01 6;:

Primary resistance to ALK inhibitors in -rearranged pleural metastatic lung adenocarcinoma: a case report.

Siblini L, Schott R, Trensz P, Pencreach E, Bender L

Transl Lung Cancer Res. 2023 11 30;12(11):2342-2346

Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review.

Moinard-Butot F, Nannini S, Fischbach C, Abdallahoui S, Demarchi M, Petit T, Bender L, Schott R

Cancers (Basel). 2023 10 11;15(20):

Solitary acrometastasis of the phalanx as initial presentation of an oligometastatic Kirsten rat sarcoma viral oncogene homolog-mutated lung adenocarcinoma: a case report.

Pușcașu AI, Moinard-Butot F, Antoni D, Schott R, Somme L

J Med Case Rep. 2023 09 18;17(1):395

Second Cancer affecting the Central Nervous System: Systematic Literature Review Exploring the Link between Malignant Melanoma and Glioblastoma.

Todeschi J, Dannhoff G, Chibbaro S, Segbedji F, Spatola G, Mallereau CH, Noel G, Schott R, Lhermitte B, Cebula H, Ganau M

World Neurosurg. 2023 08 23;:

Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting.

Belaroussi Y, Bouteiller F, Bellera C, Pasquier D, Perol M, Debieuvre D, Filleron T, Girard N, Schott R, Mathoulin-Pélissier S, Martin AL, Cousin S

Sci Rep. 2023 06 13;13(1):9584

Exacerbated central fatigue and reduced exercise capacity in early-stage breast cancer patients treated with chemotherapy.

Hucteau E, Mallard J, Pivot X, Schott R, Pflumio C, Trensz P, Favret F, Pagano AF, Hureau TJ

Eur J Appl Physiol. 2023 03 20;:

p16 Immunohistochemical Expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas Leading to Prognostic Significances.

Geyer L, Wolf T, Chenard MP, Cebula H, Schott R, Noel G, Guerin E, Pencreach E, Reita D, Entz-Werlé N, Lhermitte B

Cancers (Basel). 2023 02 28;15(5):

Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications.

Lhermitte B, Wolf T, Chenard MP, Coca A, Todeschi J, Proust F, Hirsch E, Schott R, Noel G, Guerin E, Reita D, Chammas A, Salmon A, Martin S, Dontenwill M, Entz-Werlé N

Cancers (Basel). 2023 02 16;15(4):

Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancer.

Mallard J, Hucteau E, Schott R, Trensz P, Pflumio C, Kalish-Weindling M, Favret F, Pivot X, Hureau TJ, Pagano AF

Cancer. 2022 11 17;:

Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.

Justeau G, Huchot E, Simonneau Y, Roa M, Le Treut J, Le Garff G, Bylicki O, Schott R, Bravard AS, Tiercin M, Lamy R, De Chabot G, Marty A, Moreau D, Locher C, Bernier C, Chouaid C, Descourt R

Lung Cancer. 2022 10 26;174:45-49

Development of skeletal muscle atrophy and intermuscular adipose tissue in early breast cancer patients treated with chemotherapy.

Mallard J, Hucteau E, Bender L, Charlot A, Debrut L, Pflumio C, Trensz P, Schott R, Favret F, Pivot X, Hureau TJ, Pagano AF

Am J Physiol Cell Physiol. 2022 09 12;:

Outcome of lung oligometastatic patients treated with stereotactic body irradiation.

Virbel G, Cox DG, Olland A, Falcoz PE, Le Fevre C, Schott R, Antoni D, Noel G

Front Oncol. 2022 07 18;12:945189

Ellipsoid calculations versus manual tumor delineations for glioblastoma tumor volume evaluation.

Le Fèvre C, Sun R, Cebula H, Thiery A, Antoni D, Schott R, Proust F, Constans JM, Noël G

Sci Rep. 2022 06 22;12(1):10502

[Impact of NGS results on patient outcome with a multiform glioblastoma].

Rom M, Schott R, Pencreac'h E, Cébula H, Cox D, Bender L, Antoni D, Lhermitte B, Noel G

Cancer Radiother. 2022 06 14;:

Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review.

Nannini S, Koshenkova L, Baloglu S, Chaussemy D, Noël G, Schott R

J Neurooncol. 2022 Apr 13;:

Chemotherapy impairs skeletal muscle mitochondrial homeostasis in early breast cancer patients.

Mallard J, Hucteau E, Charles AL, Bender L, Baeza C, Pélissie M, Trensz P, Pflumio C, Kalish-Weindling M, Gény B, Schott R, Favret F, Pivot X, Hureau TJ, Pagano AF

J Cachexia Sarcopenia Muscle. 2022 Apr 4;:

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.

Descourt R, Pérol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cadranel J, Cortot AB, Guisier F, Galland L, Do P, Schott R, Dansin É, Arrondeau J, Auliac JB, Geier M, Chouaïd C

Cancers (Basel). 2022 Mar 30;14(7):

Interventional Magnetic-Resonance-Guided Cryotherapy Combined with Microsurgery for Recurrent Glioblastoma: An Innovative Treatment?

Cebula H, Garnon J, Todeschi J, Noel G, Lhermitte B, Mallereau CH, Chibbaro S, Burckel H, Schott R, Mathelin M, Gangi A, Proust F

Neurochirurgie. 2021 Dec 11;:

Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort.

Girard N, Perol M, Simon G, Audigier Valette C, Gervais R, Debieuvre D, Schott R, Quantin X, Coudert B, Lena H, Carton M, Robain M, Filleron T, Chouaid C

Lung Cancer. 2021 Nov 6;162:119-127

A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes.

Chouaid C, Filleron T, Debieuvre D, Pérol M, Girard N, Dansin E, Lena H, Gervais R, Cousin S, Otto J, Schott R, Planchard D, Madroszyk A, Kaderbhai C, Dubray-Longeras P, Hiret S, Pichon E, Clément-Duchêne C, Chenuc G, Simon G, Bosquet L, QUantin X

Target Oncol. 2021 Oct 18;:

First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.

Descourt R, Chouaid C, Pérol M, Besse B, Greillier L, Bylicki O, Ricordel C, Guisier F, Gervais R, Schott R, Auliac JB, Robinet G, Decroisette C

Future Oncol. 2021 Jun 22;:

Pseudoprogression versus true progression in glioblastoma patients: a multiapproach literature review. Part 2 - Radiological features and metric markers.

Le Fèvre C, Constans JM, Chambrelant I, Antoni D, Bund C, Leroy-Freschini B, Schott R, Cebula H, Noël G

Crit Rev Oncol Hematol. 2021 Jan 27;:103230

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.

Demarchi M, Coliat P, Barthelemy P, Schott R, BenAbdelghani M, Kim M, Hii JCS, Feyaerts P, Ang FRX, Derde MP, Deforce F, Petit T, Schwabe C, Wynne C, Park LS, Pivot X

PLoS One. 2021 ;16(9):e0248222

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis.

Monnet I, Vergnenègre A, Robinet G, Berard H, Lamy R, Falchero L, Vieillot S, Schott R, Ricordel C, Chouabe S, Thomas P, Gervais R, Madroszyk A, Abdiche S, Chiappa AM, Greillier L, Decroisette C, Auliac JB, Chouaïd C,

Ther Adv Med Oncol. 2021 ;13:17588359211006983

Pseudoprogression versus true progression in glioblastoma patients: a multiapproach literature review: Part 1 - Molecular, Morphological and Clinical features.

Le Fèvre C, Lhermitte B, Ahle G, Chambrelant I, Cebula H, Antoni D, Kelle Zr A, Schott R, Thiery A, Noël G

Crit Rev Oncol Hematol. 2020 Dec 8;:103188

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.

Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, Letreut J, Le Caer H, Gervais R, Dansin E, Madroszyk A, Renault PA, Le Garff G, Falchero L, Berard H, Schott R, Saulnier P, Chouaid C,

Lancet Oncol.. 2020 Sep;21(9):1224-1233

Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol.

Mallard J, Hucteau E, Schott R, Petit T, Demarchi M, Belletier C, Ben Abdelghani M, Carinato H, Chiappa P, Fischbach C, Kalish-Weindling M, Bousinière A, Dufour S, Favret F, Pivot X, Hureau TJ, Pagano AF

Front Oncol. 2020 ;10:1304

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).

Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C

Lung Cancer. 2019 Aug 14;136:109-114

Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report.

Burgy M, Chenard MP, Noël G, Bourahla K, Schott R

J Med Case Rep. 2019 Jun 28;13(1):202

An integrated genomic and metabolomic approach for defining survival time in adult oligodendrogliomas patients.

Bund C, Guergova-Kuras M, Cicek AE, Moussallieh FM, Dali-Youcef N, Piotto M, Schneider P, Heller R, Entz-Werle N, Lhermitte B, Chenard MP, Schott R, Proust F, Noël G, Namer IJ

Metabolomics. 2019 Apr 29;15(5):69

Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database.

Girard N, Pérol M, Simon G, Audigier Valette C, Gervais R, Debieuvre D, Schott R, Quantin X, Coudert B, Lena H, Carton M, Robain M, Filleron T, Chouaid C

Ann. Oncol.. 2019 Apr;30 Suppl 2:ii34

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gerinière L, Renault A, Daniel C, Falchero L, Chouaid C

Lung Cancer. 2019 Jan;127:96-102

Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review.

Lesueur P, Martel-Laffay I, Escande A, Kissel M, Locher C, Gervais R, Schott R, Vergnenegre A, Chouaid C

Expert Rev Anticancer Ther. 2018 Sep 1;:

Pre- and post-surgery MRSI predictive value in adult oligodendroglioma prognosis.

Bund C, Lefebvre F, Schott R, Chenard MP, Lhermitte B, Cebula H, Kremer S, Proust F, Namer IJ

Magn Reson Imaging. 2018 Jun 11;:

Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.

Dupont B, Mariotte D, Dugué AE, Clarisse B, Grellard JM, Babin E, Chauffert B, Dakpé S, Moldovan C, Bouhier-Leporrier K, Reimund JM, Di Fiore F, Zanetta S, Mailliez A, Do P, Peytier A, Galais MP, Florescu C, Schott R, Le Mauff B, Gervais R

Br J Clin Pharmacol. 2017 Mar;83(3):623-631

[Bevacizumab in combination with first-line treatment for metastatic non-small cell lung cancer in clinical practice. Results of the EOLE study].

Chouaid C, Falchero L, Schott R, Bonnetain F, Taguieva-Pioger N, Bennouna J

Rev Mal Respir. 2017 Jan;34(1):36-43

Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.

Paquette B, Vernerey D, Chauffert B, Dabakuyo S, Feuvret L, Taillandier L, Frappaz D, Taillia H, Schott R, Ducray F, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O, Anota A, Bonnetain F

Cancer Med. 2016 Aug;5(8):1753-64

Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.

Antoni D, Jastaniah Z, Haoming QC, Gaultier C, Ahle G, Couchot J, Atlani D, Schott R, Clavier JB, Srour R, Chaussemy D, Noël G

Cancer Radiother. 2016 Jun;20(4):282-91

Bevacizumab in Patients with Non-Squamous Non-Small-Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): a Non-Randomised, Phase II Study.

Besse B, Le Moulec S, Maazieres J, Senellart H, Barlesi F, Chouaid C, Dansin E, Berard H, Falchero L, Gervais R, Robinet G, Ruppert AM, Schott R, Lena H, Clement-Duchene C, Quantin X, Souquet PJ, Tredaniel J, Moro-Sibilot D, Perol M, Madroszyk AC, Soria JC

Clin Cancer Res. 2015 Jan 22. pii: clincanres.2082.2014.

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.

Auliac JB, Chouaid C, Greiller L, Monnet I, Le Caer H, Falchero L, Corre R, Descourt R, Bota S, Berard H, Schott R, Bizieux A, Fournel P, Labrunie A, Marin B, Vergnenegre A

Lung Cancer. 2014 Sep;85(3):415-9

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEFdagger.

Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, Schott R, Honnorat J, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O

Ann Oncol. 2014 Jul;25(7):1442-7

A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer.

Lerouge D, Riviere A, Dansin E, Chouaid C, Dujon C, Schott R, Lavole A, Le Pennec V, Fabre E, Crequit J, Martin F, Dehette S, Fournel P, Precheur-Agulhon B, Lartigau E, Zalcman G

BMC Cancer. 2014 Mar 30;14:231

[An analysis of 20 consecutive patients treated with stereotactic body radiotherapy on Novalis Tx((R)) for stage I non-small-cell lung cancer].

Guillerme F, Clavier JB, Schumacher C, Falcoz PE, Bourrhala K, Santelmo N, Hassler S, Schott R, Quoix E, Massard G, Noel G

Cancer Radiother. 2013 Jul-Aug;17(4):272-81

Pemetrexed-induced skin sclerosis.

Merklen-Djafri C, Imbert E, Courouge-Dorcier D, Schott R, Meraud JP, Muller C, Tebacher M, Springinsfeld G, Cribier B, Lipsker D

Clin Oncol (R Coll Radiol). 2012 Aug;24(6):452-3

Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.

Noel G, Schott R, Froelich S, Gaub MP, Boyer P, Fischer-Lokou D, Dufour P, Kehrli P, Maitrot D

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):749-55

Fiche personne

Coordonnées

Territoire

Statut

Affiliation

Équipes/plateformes

Publications

Retrouvez aussi